Unichem Laboratories receives USFDA approval for Apremilast Tablets
Capital MarketUnichem Laboratories has received ANDA approval for its Apremilast Tablets, 10 mg, 20 mg and 30 mg from the United States Food and
Drug Administration (USFDA) to market a generic version of Amgen's Otezla (apremilast) Tablets, 10 mg, 20 mg, and 30 mg.
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content